Public Awareness on Cancer-Associated Thrombosis among the Greek Population: First Findings from the ROADMAP-CAT Awareness Study

Kyriakos Souliotis¹,², Christina Golna³, Sofia Nikolaidi², Patrick V. Dreden⁴,⁵, Georgia Vatheia², Grigoris T. Gerotziafas⁴,⁶

¹ Department of Social and Education Policy, University of Peloponnese, Corinth, Greece
² Research Department, Health Policy Institute, Maroussi, Athens, Greece
³ Policy Change Department, Innowth, Larnaca, Cyprus
⁴ Sorbonne University, Institut National de la Santé et de la Recherche Médicale (INSMR), Unit 938, Research Group Cancer, Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France
⁵ Department of Clinical Research, Diagnostica Stago, Gennevilliers, France
⁶ Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l’Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France

Address for correspondence Kyriakos Souliotis, PhD, Health Policy Institute, 8, Agisilaou Street, 15123, Maroussi, Athens, Greece (e-mail: ksouliotis@uop.gr).

Keywords
► venous thromboembolism
► deep vein thrombosis
► pulmonary embolism
► cancer
► public awareness

Abstract

Background Cancer-associated thrombosis (CAT) is the second cause of mortality after cancer itself. CAT is underestimated as a health challenge among oncologists, whereas the levels of awareness among patients and the public have not been systematically assessed and followed in the European Union countries.

Aim The Prospective Risk Assessment and Management of Patient with CAT (ROADMAP-CAT) Awareness study is an investigator-initiated, descriptive and nonexperimental study with a cross-sectional design and it explores CAT risk awareness among cancer patients and the general public in Greece to provide an impetus for health policy interventions and a benchmark against which impact of any future interventions may be assessed.

Methods A total of 1,003 participants aged above 18 years were contacted by phone after random selection from the national telephone catalogue. Participation was voluntary and completely anonymous, and a structured questionnaire was used to elicit responses. Data were analyzed using IBM SPSS version 25.

Results Among respondents, almost one-third (32.3%) reported CAT awareness, while only one in five (21.7%) were aware of the signs and symptoms of venous thromboembolism (VTE). Among patients with a personal history of cancer or of VTE, 47 and 58%, respectively, were aware of CAT risk. Of those aware of the association, 35.2% identified their treating physician as the main source of information. The level of awareness did not significantly differ by responders’ demographics.

Conclusion The ROADMAP-CAT Awareness study revealed very low levels of awareness on CAT and VTE risk both among the general public and cancer patients in Greece.

DOI https://doi.org/10.1055/a-1742-0465.
ISSN 2512-9465.

© 2022. The Author(s).
This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
Awareness of the signs and symptoms of VTE was also particularly low. Treating physicians are not actively engaging in educating their patients about CAT. Public awareness of the increased risk of VTE among cancer patients is critical to prevent and diagnose the disease early. It is imperative that a structured campaign supports medical professionals to take the time to increase awareness and educate their patients on this matter if to improve morbidity and mortality of cancer patients.

Introduction

The association between cancer and venous thromboembolism (VTE) is well-known in the medical community and in this specific case, it is described by the term “cancer-associated thrombosis (CAT).” The risk of CAT is increased four to seven fold in patients with cancer compared with those without malignancy. Despite CAT being a preventable disease, it is a leading cause of mortality among cancer patients after cancer itself. A retrospective population-based study which analyzed data from 15.7 million adult persons with cancer living in the United States showed that the overall annual incidence of CAT varied between 1.80 and 0.72% in the period 2005 to 2014, with an overall average incidence of 1.16%. Nevertheless, the incidence of CAT varied according to the type of cancer. Pancreatic cancer and anorectal cancer were associated with the highest risk of CAT. Other types of cancer, such as uterine and cervical cancer, were associated with a lower risk of CAT. Patients who were on public insurance or uninsured were more likely to have CAT than patients who were on private insurance (1.24, 1.30, and 0.92%, respectively; \( p < 0.0001 \)). Noteworthy, throughout the study period, the annual incidence of CAT decreased by 60%, but overall following an insignificant nonlinear downward trend, underlying that prevention of CAT remains an unmet need.

The risk of CAT increases by approximately six fold in outpatients on anticancer treatment or with advanced stage of the disease. The mortality rate of patients with CAT is two- to three-fold higher compared with those without. Furthermore, CAT occurrence leads to modifications of the anticancer treatment schedule. Patients diagnosed with CAT must receive long-term anticoagulant therapy which exposes them to a significantly higher risk of major bleeding, thus compromising the administration of anticancer treatment. In addition, CAT figures among the leading causes for prolonged hospitalization and readmissions, thus causing a substantial economic burden on the health systems. The direct cost of CAT in the European Union (EU) health systems is estimated to account for €1.5 to 2.2 billion each year, mostly due to hospitalizations. In France, for instance, CAT is the most frequent diagnosis leading to hospital admission in patients with breast or prostate cancer. The average cost per stay for the first thrombotic event is about €3,611.

CAT is an underestimated problem in the community of oncologists, despite its major impact on patient survival and quality of life and health system economics. Routine assessment of risk for CAT is recommended by international and national guidelines. However, according to the European Society of Medical Oncology (ESMO) “most oncologists underestimate the prevalence of CAT and its negative impact on their patients.” According to the most modern concept acknowledged by the recent recommendations published by American Society of Clinical Oncology (ASCO) experts, Oncologists and members of the oncology team should educate patients regarding CAT.

Thus, patients are assigned an increasingly important role in the implementation of thromboprophylaxis for CAT. In addition, proper education of patients with cancer on the recognition of signs and symptoms of VTE can lead to prompt diagnosis and a more effective treatment. Nevertheless, the levels of awareness for CAT either among patients with cancer or in the public remain low. The evaluation of the actual state of public awareness for CAT is important for the elaboration of targeted successful communication strategies.

In Greece, public awareness of the association between malignancy and VTE is assumed to be low, particularly as the topic is largely overlooked in cancer patient information and support materials. To this end, the Prospective Risk Assessment and Management of Patient with CAT (ROADMAP-CAT) Awareness study investigated the degree of actual public awareness on the risk of CAT in a single European country (Greece) and identified variables which could contribute to the success of the communication strategy.

Materials and Methods

Study Design and Participants

The study was an investigator-initiated, descriptive, nonexperimental with a cross-sectional design and data were collected from September 29 to October 3, 2017. Telephone numbers were selected randomly from the national telephone catalogue and stratified according to the respondents’ place of residence. Regarding the sample composition, it was weighted in terms of gender and age to match the 2011 population census, so as to be representative of the general Greek population. Participants were contacted by phone, and a standardized questionnaire was provided to the respondents with the use of computer-assisted telephone interviewing (CATI). Respondents remained anonymous throughout the whole process. When the respondent agreed to participate in the survey, an interviewer read the questions and filled in the questionnaire directly on his/her
computer screen. The questionnaire was developed in cooperation with clinical experts and was pilot tested on 100 respondents before the finalization. Those responses were excluded from the final sample. Questionnaires enquired after (1) awareness of the correlation between cancer and VTE, (2) awareness of the symptoms of VTE, and (3) sources of information (e.g., physicians, relatives, and the internet). Demographic data, such as age, gender, income, and region of residence, were also collected. A section on respondents’ general health and access to health services over the past 6 months was also included in the questionnaire. In total, 1,374 telephone calls were made and 73% accepted to participate in the survey.

**Statistical Analysis**

The number of participants included in the study was calculated using G’Power 3.1 software, employing the following input parameters: df = 1, correlation = 0.12 (as estimates in the research area of interest are unknown, an estimate indicative of small effect was used), power = 0.95, error probability = 0.05, and indicated that the sample size should be 903 participants. Descriptive statistics are presented using absolute and relative frequencies. Awareness of the association between VTE and cancer was assessed according to several characteristics that included age, gender, level of education, and personal and family history of cancer. For the comparison of categorical data, Chi-square tests were performed. All statistical analyses were performed using IBM SPSS version 25.

**Results**

Overall, 1,003 questionnaires were completed. All respondents were 18 years of age and over. There were no exclusion criteria. A small percentage of respondents in the general public were expected to have a personal history of VTE. Therefore, responders were asked if they had ever suffered from VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) in the past, without being excluded if their response was positive.

Among 1,003 participants in the study sample, the majority were women (54.4%), 82.9% were aged over 40 years, 71.5% were married, and 43% were secondary education graduates. Also, 67.2% resided in urban areas, 60.8% considered their income as low or low to medium, and 34.7% considered their income as medium. Among participants, 5.1% had been diagnosed with cancer. Moreover, 48.6% mentioned having a relative or close acquaintance with a cancer diagnosis and 46.1% had no cancer diagnosis experience in their social environment. Demographics data of respondents are summarized in Table 1.

### Table 1 Demographic characteristics (n = 1,003)

| Category                        | n   | %   |
|---------------------------------|-----|-----|
| Gender                          |     |     |
| Men                             | 457 | 45.6|
| Women                           | 546 | 54.4|
| Age (y)                         |     |     |
| 18–24                           | 35  | 3.5 |
| 25–39                           | 136 | 13.6|
| 40–54                           | 332 | 33.1|
| 55–64                           | 202 | 20.1|
| 65+                             | 298 | 29.7|
| Educational statusa             |     |     |
| Primary education               | 148 | 14.8|
| Secondary education             | 430 | 43.0|
| University degree               | 355 | 35.5|
| Postgraduate degree–PhD         | 66  | 6.6 |
| Marital statusb                 |     |     |
| Single                          | 132 | 13.2|
| Cohabitate                      | 14  | 1.4 |
| Married                         | 715 | 71.5|
| Divorced                        | 47  | 4.7 |
| Widowed                         | 92  | 9.2 |
| Region of residence             |     |     |
| Attica                          | 382 | 38.1|
| Northern Greece                 | 257 | 25.6|
| Central Greece                  | 269 | 26.8|
| Aegean-Crete                    | 95  | 9.5 |
| Place of residence              |     |     |
| Urban                           | 674 | 67.2|
| Rural                           | 329 | 32.8|
| Incomec                         |     |     |
| Low                             | 409 | 41.5|
| Low to medium                   | 190 | 19.3|
| Medium                          | 342 | 34.7|
| Medium to high                  | 41  | 4.2 |
| High                            | 4   | 0.4 |
| History of cancer diagnosisd    |     |     |
| Personal                        | 51  | 5.1 |
| Family or close acquaintance    | 487 | 48.7|
| No                              | 462 | 46.2|
| Personal history of VTEe        |     |     |
| Yes                             | 24  | 2.4 |
| No                              | 962 | 97.6|

Abbreviation: VTE, venous thromboembolism.

*Missing values, 0.4%.
*Missing values, 0.3%.
*Missing values, 1.7%.
*Missing values, 0.3%.
*Missing values, 1.7%.
Table 2 Awareness of VTE (n = 1,003)

| Are you aware of the correlation between cancer and VTE | n  | %  |
|---------------------------------------------------------|----|----|
| No                                                      | 679| 67.7|
| Yes                                                     | 324| 32.3|
| Are you aware of the signs and symptoms of venous thromboembolism, that include shortness of breath, lower limb pain, swelling and redness\(^a\) |    |    |
| No                                                      | 729| 72.9|
| Yes                                                     | 271| 27.1|

Abbreviation: VTE, venous thromboembolism.
\(^a\)Missing values, 0.3%.

72.9% of participants were unable to recognize signs and symptoms of VTE (\textit{Table 2}).

No statistically significant association was found between awareness levels and sociodemographic characteristics. However, personal history of cancer and VTE were univariately associated with higher rates of awareness. The percentage of participants reporting awareness of the association between VTE and cancer was significantly higher among those with personal history of VTE or cancer: 58.3 versus 32.2%, \(p < 0.05\), respectively. Results are depicted in \textit{Table 3}.

Source of Information Regarding Venous Thromboembolism

The 321 (32%) responders who were aware that cancer patients have a higher probability of VTE were asked to identify their main source of information; 35.2% mentioned their physicians as their primary source of information and 38.7% reported being informed by nonphysicians in their social circle (\textit{Table 4}).

Only one in five (20.3% [\(n = 43\)]) of respondents who did not identify their physician as their primary source of information confirmed that their treating physician had ever discussed this topic with them.

Discussion

The aim of the present study was to investigate the awareness on CAT and VTE among the general public in Greece. The study focused on the different factors that might affect the degree of awareness and investigate the involvement of medical professionals in public information provision.

The study highlights a generally poor public awareness of CAT. Two-thirds of respondents were unaware of CAT and 72.9% ignored the signs and symptoms of VTE. These findings are consistent with results from similar studies worldwide. Lack of awareness of CAT appears not to be influenced by sociospatial factors, the age, or the educational status of the participants. Personal history of VTE or cancer was associated with higher awareness for CAT as compared with the general population. Nevertheless, levels of awareness of 52.9% among participants with personal history of cancer reveal that that education of cancer patients on CAT risk and the benefits of thromboprophylaxis is still an unmet need. Our findings are in line with the statement of the European Thrombosis and Haemostasis Alliance (ETHA) which recognizes that low awareness for VTE symptoms, risk factors, and causes of thrombosis in the general public leads to a lack of understanding and thus a lack of notice by policymakers.\(^5\) This lack is accentuated in patients with cancer because CAT is the second cause of death after cancer itself. Increasing awareness on CAT, as well as early recognition of signs and symptoms associated with VTE, particularly in patients with cancer, is expected to lead at the increase of thromboprophylaxis use and, consequently, reduction in VTE-related deaths.

Our findings also highlighted that the role of the treating physician was almost similar to that of friend, relative, or acquaintance, as regard to information provision on CAT to patients. This finding reflects a limited intervention of the medical community in public communication about CAT and, particularly, in patients with cancer. Although a routine assessment to identify patients at high risk for CAT is recommended by international and national guidelines, according to the European Society of Medical Oncology (ESMO) “most oncologists underestimate the prevalence of CAT and its negative impact on their patients.”\(^12,13,16\) Data from large multinational and national surveys on patients at risk of CAT and the experience from academic medical centers involved in the management of thrombosis reveal the failure or reluctance to apply guidelines on the prophylaxis of CAT. For example, only 54% of patients receiving chemotherapy are made aware of the risk of CAT. In one French cohort, only 55% of cancer patients at risk of CAT received thromboprophylaxis.\(^23\) In the United Kingdom, only 41% of hospital trusts have a policy for managing VTE. The reported rates of implementation of the guidelines for thromboprophylaxis in hospitalized cancer patients are lower than 18%, while the corresponding rates for hospitalized noncancer patients are higher than 50%.\(^24\)

Our ROADMAP-CAT Awareness study findings strongly support the need for a targeted communication program aimed to the general public, patients with cancer and their treating physicians on the burden of CAT, risk assessment methods, and recommended strategies for thromboprophylaxis. The data presented herein describe the actual status of awareness for CAT and will serve in the evaluation of the efficacy of targeted interventions aimed at improving current picture.

Limitations and Strengths

Our study was conducted in the general population and therefore cannot be referred at to provide insights into specific subgroups of people, such as hospitalized patients or other at-risk populations.\(^25,26\) The findings of this study could potentially be generalized as the sample was derived from the general public with no exclusion criteria applied.
Conclusion

In conclusion, the ROADMAP-CAT Awareness study showed a low level of awareness on CAT in the general public and in patients with cancer. Awareness of the signs and symptoms of VTE is also particularly low. Treating physicians are not actively engaged in educating their patients and the general public about CAT. This general lack of awareness combined with the apparently low prioritization of any organized awareness campaigns on the association between cancer and VTE may be seriously undermining the morbidity and mortality associated with CAT.

Table 3 Number and percentage of respondents reporting awareness of the association between cancer and VTE by respondent characteristics ($n = 1,003$)

| Characteristic                        | No ($n = 679$) | Yes ($n = 324$) | $p$-Value$^a$ |
|---------------------------------------|----------------|-----------------|---------------|
| Personal history of VTE              |                |                 |               |
| No                                    | 652 (67.8)     | 310 (32.2)      | 0.007         |
| Yes                                   | 10 (41.7)      | 14 (58.3)       |               |
| Personal history of cancer            |                |                 |               |
| No                                    | 649 (68.4)     | 300 (31.6)      | 0.022         |
| Yes                                   | 27 (52.9)      | 24 (47.1)       |               |
| Family history of cancer              |                |                 |               |
| No                                    | 342 (66.7)     | 171 (33.3)      | 0.517         |
| Yes                                   | 334 (68.6)     | 153 (31.4)      |               |
| Gender                                |                |                 |               |
| Male                                  | 321 (70.2)     | 136 (29.8)      | 0.115         |
| Female                                | 358 (65.6)     | 188 (34.4)      |               |
| Age (y)                               |                |                 |               |
| 18–24                                 | 25 (71.4)      | 10 (28.6)       | 0.101         |
| 25–39                                 | 95 (69.9)      | 41 (30.1)       |               |
| 40–54                                 | 126 (70.1)     | 46 (29.9)       |               |
| 55–64                                 | 226 (68.1)     | 106 (31.9)      |               |
| 65+                                   | 121 (59.9)     | 81 (40.1)       |               |
| Income                                |                |                 |               |
| Low to medium                         | 407 (67.9)     | 192 (32.1)      | 0.880         |
| Medium                                | 231 (67.5)     | 111 (32.5)      |               |
| Medium to high                        | 29 (64.4)      | 16 (35.6)       |               |
| Place of residence                    |                |                 |               |
| Urban                                 | 452 (67.1)     | 222 (32.9)      | 0.538         |
| Rural                                 | 227 (69.0)     | 102 (31.0)      |               |
| Educational level                     |                |                 |               |
| Primary education                     | 106 (71.6)     | 42 (28.4)       | 0.420         |
| Secondary education                   | 292 (67.9)     | 138 (32.1)      |               |
| Tertiary education                    | 277 (65.8)     | 144 (34.2)      |               |

Abbreviation: VTE, venous thromboembolism.

Table 4 Primary source of information on the association between VTE and cancer ($n = 324$)

| Source                          | $n$  | %   |
|---------------------------------|------|-----|
| Treating or other physician     | 112  | 35.2|
| A friend, relative or acquaintance | 123  | 38.7|
| The internet                    | 51   | 16.0|
| Brochures                       | 32   | 10.1|

Abbreviation: VTE, venous thromboembolism.

Note: Missing values, 0.6%.

Note: Missing values, 0.6%.
mortality indicators of cancer patients, as well as contributing to the burden cancer places on patients and family. The organization of well-designed outreach, informative campaigns on CAT, targeting particularly cancer patients, general practitioners, and oncologists is an urgent need to improve morbidity and mortality of cancer patients.

What Is Known about This Topic?

- Cancer-associated thrombosis (CAT) is an underestimated problem despite its substantial impact on patient survival and quality of life and health system economics.
- Oncologists and members of the oncology team should educate patients on cancer associated thrombosis.
- Patients’ knowledge of and understanding of CAT risk is expected to improve guideline implementation and increase adherence to thromboprophylaxis.
- In Greece, a country with high cancer prevalence and incidence, CAT awareness and understanding among cancer patients and the general public is underresearched, despite its potential impact on patient survival. Equally, there is very limited communication on the matter from cancer patient associations and/or relevant information sources.

What Does This Paper Add?

- Our study confirms very low levels of awareness of CAT risks and prevention among both cancer patients and the public in Greece as elsewhere.
- Findings of our study reported in this paper are expected to raise awareness of the actual unmet need, among health system administrators, oncology scientific societies, and patient associations and to instigate a joint effort to improve indicators through education.
- Our study adds to the existing literature and highlights an area of unmet need in cancer that is underresearched, thus hopefully, prompting more research across health systems. This would facilitate cross-system comparisons and best practice sharing to achieve optimal CAT awareness and risk management.

Ethics

Participation in this study was on a voluntary basis. All respondents were informed of the voluntary nature of the survey. The study was approved by the local institutional ethics committee.

Funding

This work was supported by an unrestricted research grant from Leo Pharma Hellas.

Conflict of Interest

G.T.G. received honoraria and unrestricted research grants from Sanofi and Leo.

The other authors have no relevant conflict of interest to declare.

References

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110(10):2339–2346
2. Michael H, Kroll MH, Pemmaraju N, Oo TH, Afshar-Kharghan V, Kroll S. Mortality from cancer-associated venous thromboembolism. Blood 2014;124:4829
3. Wun T, White RH. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009;22(01):9–23
4. Almohammed OA, Latif L, Khanfar NM, Bleidt B, Aljadhey H. Trends of cancer-associated venous thromboembolism (VTE) in the United States (2005–2014). Thromb Res 2019;182:110–115
5. Tran BH, Nguyen TJ, Hwang BH, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast 2013;22(04):444–448
6. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011;29(25):3466–3473
7. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484–3488
8. Lyman GH, Khorana AA, Falanga A. Thrombosis and cancer: emerging data for the practicing oncologist. Am Soc Clin Oncol Educ Book 2013
9. European Thrombosis & Haemostasis Alliance. European Thrombosis & Haemostasis Alliance consensus statement. Accessed February 1, 2022 at: http://etha.eu/wp-content/uploads/2018/03/European-Thrombosis-Consensus-Statement.pdf
10. Scottie F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. Adv Ther 2015;32(2):138–147
11. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2_suppl):e195S–e226S
12. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism–International Consensus Statement. Int Angiol 2013;32(02):111–260
13. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013;11(01):71–80
14. Farge D, Frere C, Connors JM, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019;20(10):e566–e581
15. Wang TF, Zwicker JJ, Ay C, et al. Use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost 2019;17(10):1772–1778
16. Mandalà M, Falanga A, Roila FESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(Suppl 6):vi85–vi92
17. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020;38(05):496–520
18. Le Sage S, McGee M, Emed JD. Knowledge of venous thromboembolism (VTE) prevention among hospitalized patients. J Vasc Nurs 2008;26(04):109–117
19 Mahé I, Chidiac J, Helfer H, Noble S. Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. J Thromb Haemost 2016;14(11):2107–2113
20 Cohen J. A power primer. Psychol Bull 1992;112(01):155–159
21 Lovakov A, Agadullina ER. Empirically derived guidelines for interpreting effect size in social psychology. Eur J Soc Psychol 2021;51(03):485–504
22 Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G’Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009;41(04):1149–1160
23 Sevestre MA, Belizna C, Durant C, et al; Carmen Investigators for the Groupe Francophone Thrombose et Cancer (GFTC) Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 2014;39(03):161–168
24 Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost 2016;14(09):1773–1778
25 Alzoubi KH, Khassawneh BY, Obeidat B, Asfoor SS, Al-azzam SL. Awareness of patients who undergo cesarean section about venous thromboembolism prophylaxis. J Vasc Nurs 2013;31(01):15–20
26 Haymes A. Venous thromboembolism: patient awareness and education in the pre-operative assessment clinic. J Thromb Thrombolysis 2016;41(03):459–463